Shi Fubiao, Agrawal Vineet, McKinsey Timothy A, Collins Sheila
Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Tennessee Valley Healthcare System Nashville Veteran Affairs Hospital, Nashville, TN 37212, USA.
Endocrinology. 2025 May 19;166(7). doi: 10.1210/endocr/bqaf092.
Salt-inducible kinases (SIKs) are a subfamily of the adenosine monophosphate-activated protein kinase-related kinase family. To be activated, SIKs require phosphorylation in the catalytic kinase domain by liver kinase B1. In response to extracellular stimulations, their activity can be further regulated through phosphorylation by protein kinase A (PKA), and Ca2+/calmodulin-dependent protein kinases. PKA-mediated SIK inhibition is a major link between G-protein coupled receptor activation and the target gene transcription program. All 3 SIK isoforms-SIK1, SIK2, and SIK3-are expressed in adipocytes, with SIK2 being the most abundant in both rodents and humans. SIKs play essential roles in maintaining adipose tissue homeostasis by regulating physiological processes involving insulin signaling, glucose uptake, lipogenesis, and thermogenesis. Each SIK isoform could play both redundant and unique roles in these physiological processes. Many of the substrates that mediate their physiological functions in adipocytes have been characterized, and downstream mechanisms of action have also been proposed. However, due to the functional redundancy of SIKs, a major challenge is to delineate their isoform-specific roles in adipose tissue in vivo using genetic mouse models. In addition, common genetic variants and rare mutations in the SIK genes have been identified to be associated with metabolic, cardiovascular, and developmental conditions, suggesting a translational implication for human disease that deserves investigation. Furthermore, small molecular SIK inhibitors have been developed and have shown therapeutic potential in multiple disease areas. Evaluation of their metabolic and cardiovascular effects will be required for future clinical development of SIK inhibitors.
盐诱导激酶(SIKs)是与单磷酸腺苷激活的蛋白激酶相关激酶家族的一个亚家族。要被激活,SIKs需要在催化激酶结构域中被肝脏激酶B1磷酸化。响应细胞外刺激,它们的活性可通过蛋白激酶A(PKA)和钙/钙调蛋白依赖性蛋白激酶的磷酸化进一步调节。PKA介导的SIK抑制是G蛋白偶联受体激活与靶基因转录程序之间的主要联系。所有三种SIK亚型——SIK1、SIK2和SIK3——都在脂肪细胞中表达,其中SIK2在啮齿动物和人类中含量最为丰富。SIKs通过调节涉及胰岛素信号传导、葡萄糖摄取、脂肪生成和产热的生理过程,在维持脂肪组织稳态中发挥重要作用。每种SIK亚型在这些生理过程中可能发挥冗余和独特的作用。许多在脂肪细胞中介导其生理功能的底物已被鉴定,并且也提出了下游作用机制。然而,由于SIKs的功能冗余,一个主要挑战是使用基因小鼠模型在体内描绘它们在脂肪组织中的亚型特异性作用。此外,已确定SIK基因中的常见遗传变异和罕见突变与代谢、心血管和发育状况有关,这表明对人类疾病具有值得研究的转化意义。此外,小分子SIK抑制剂已被开发出来,并在多个疾病领域显示出治疗潜力。对它们的代谢和心血管作用进行评估将是SIK抑制剂未来临床开发所必需的。